Citigroup Inc. cut its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX – Get Rating) by 30.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 89,011 shares of the biotechnology company’s stock after selling 39,670 shares during the quarter. Citigroup Inc.’s holdings in REGENXBIO were worth $2,019,000 at the end of the most recent quarter.
A number of other institutional investors have also recently bought and sold shares of RGNX. Bioimpact Capital LLC acquired a new stake in REGENXBIO during the 3rd quarter worth about $16,362,000. Goldman Sachs Group Inc. lifted its holdings in shares of REGENXBIO by 320.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 500,125 shares of the biotechnology company’s stock valued at $12,353,000 after buying an additional 381,047 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of REGENXBIO by 16.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,254,101 shares of the biotechnology company’s stock valued at $33,142,000 after buying an additional 176,607 shares during the last quarter. State Street Corp lifted its holdings in shares of REGENXBIO by 6.6% during the 1st quarter. State Street Corp now owns 2,653,766 shares of the biotechnology company’s stock valued at $88,078,000 after buying an additional 163,513 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of REGENXBIO by 253.3% during the 2nd quarter. AQR Capital Management LLC now owns 143,065 shares of the biotechnology company’s stock valued at $3,534,000 after buying an additional 102,574 shares during the last quarter. 80.21% of the stock is currently owned by institutional investors and hedge funds.
REGENXBIO Stock Performance
RGNX opened at $18.26 on Friday. The business has a 50 day moving average price of $19.24 and a 200 day moving average price of $21.43. REGENXBIO Inc. has a twelve month low of $17.03 and a twelve month high of $35.73.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on RGNX. Chardan Capital reduced their price target on REGENXBIO from $61.00 to $55.00 in a report on Thursday, May 4th. Morgan Stanley reduced their price target on REGENXBIO from $50.00 to $46.00 and set an “overweight” rating for the company in a report on Monday, March 6th. Finally, StockNews.com began coverage on REGENXBIO in a report on Thursday, May 18th. They set a “hold” rating for the company. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $40.00.
REGENXBIO, Inc is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381.
- Get a free copy of the StockNews.com research report on REGENXBIO (RGNX)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for REGENXBIO Inc. (NASDAQ:RGNX – Get Rating).
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.